{"meshTags":["Antineoplastic Agents","Breast Neoplasms","Carcinoma, Ductal, Breast","Female","Humans","Quinazolines"],"meshMinor":["Antineoplastic Agents","Breast Neoplasms","Carcinoma, Ductal, Breast","Female","Humans","Quinazolines"],"genes":["HER2","HER3 Positive","HER2","HER2"],"publicationTypes":["Comment","Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov\u0027t"],"abstract":"Targeting HER2 for the treatment of HER2-positive breast cancers is now a validated treatment paradigm. However, evidence suggests that this family of receptors may have important roles outside of the realm of HER2 amplification. There is considerable interest in the development of biomarkers to identify such breast cancers.","title":"HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive.","pubmedId":"25609069"}